What Questions to Ask Before Starting a Peptide Protocol

This is the first and most fundamental question. The answer should categorise the compound clearly: FDA-approved drug (can be used on- or off-label), Category 1 (legally compoundable with prescription while under FDA review), or Category 2 (not currently legally compoundable — the protocol would require a different justification).

Distinguish between mechanistic rationale (we understand how it should work), animal data (it works in rodent models), small human studies (limited evidence in humans), and RCTs (the highest standard). Many peptides have strong mechanisms and animal data but limited human clinical evidence. Knowing which level of evidence supports the proposed use is essential for realistic expectations.

The protocol should be tailored to your lab results, symptoms, health history, and goals — not to a standard package every patient receives. There should be a clear clinical rationale connecting your individual presentation to the compound being proposed, with alternatives considered and explained.

A legitimate clinical consultation includes what a treatment cannot do, not just what it can. A physician who only describes benefits without covering limitations is selling, not consulting. For each peptide category, there are specific things it does not address — asking this question explicitly invites a balanced clinical response.

GH secretagogues require cancer risk assessment (elevated IGF-1 and cancer history). BPC-157's pro-angiogenic properties require discussion in anyone with cancer history. Certain peptides interact with conditions like sleep apnoea, diabetes, or cardiovascular disease. Your provider should review your full health history before prescribing — not just the conditions you've volunteered.

This should receive an immediate, specific answer. The pharmacy name allows you to independently verify its state licence, check whether it appears on the PCAB accreditation directory, and confirm FDA registration status if it is a 503B facility. A provider who cannot name their pharmacy partner does not know what's in the vials they are prescribing.

A legitimate compounding pharmacy produces batch-specific Certificates of Analysis from third-party laboratories. You are entitled to see this documentation. It should include the lot number, HPLC purity result, identity confirmation, and endotoxin testing results for any injectable. If a provider or pharmacy hesitates to provide this, that is a significant quality signal.

Under current compounding regulations, the active pharmaceutical ingredient used in compounded medications must come from an FDA-registered manufacturer. Research-use-only (RUO) API cannot legally be used in compounded medications for human use. The pharmacy should be able to confirm FDA-registered sourcing, and the API supplier's registration can be verified through the FDA's database.

Baseline labs serve two purposes: determining whether the protocol is appropriate for you, and establishing the reference point against which outcomes will be measured. For GH secretagogues: IGF-1, CBC, metabolic panel, fasting insulin, and any cancer-risk relevant markers. For hormone protocols: full hormone panel plus any organ function tests. The specific labs should be named, not described vaguely.

This is the most important question to ask — and the one most clinics don't want you to ask. Some patients are not good candidates for specific peptides. A physician who reviews your labs and concludes you are not an appropriate candidate — and explains why — is performing their job correctly. A clinic that would prescribe to essentially any patient who completes the intake form is not.

Follow-up monitoring should be defined before the protocol starts, not discussed retrospectively. For GH secretagogues: IGF-1 at 6–8 weeks to confirm response, then 3 months. For hormone protocols: relevant hormone levels and safety markers at defined intervals. The monitoring schedule should be specific, and dosing adjustments should be based on objective results rather than symptoms alone.

A protocol with no defined stopping criteria is not a protocol — it is a subscription. The provider should be able to name specific lab findings, symptoms, or circumstances that would prompt stopping, dose reduction, or switching to an alternative. This reflects genuinely individualised, outcome-driven care.

Side effects should be discussed specifically, not generically reassured away. For GH secretagogues: injection site reactions, temporary fluid retention, tingling, possible cortisol/prolactin effects (older GHRPs). For GLP-1s: nausea, GI side effects, potential muscle loss. For BPC-157: limited human data means unknowns are part of the conversation. You should be given specific guidance on what warrants a call versus what is expected and self-resolving.

Peptide interactions are not always well characterised, but the provider should review your current medications actively. GH secretagogues can affect insulin sensitivity — relevant for diabetics or pre-diabetics on medication. Peptides that modulate inflammation or the immune system can interact with immunosuppressants. Your complete medication and supplement list should be reviewed, not left to your disclosure.

For GH secretagogues: abrupt cessation does not typically cause a dangerous rebound, but a gradual reduction is sometimes recommended to allow the pituitary to readjust. For protocols involving exogenous hormones: stopping suddenly can be more consequential. Understanding the exit strategy before starting is part of informed consent, not an afterthought.